Nasdaq
$5.86▲ 0.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $553.2MShares out 94.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 4d agoPre-market26.10.20 21:368-KKey event#●●●#●●●
MYRIAD GENETICS INCBullish
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, FirstGene, and SneakPeek tests, to Labcorp for $210 million in cash plus the value of inventory. The transaction is designed to strengthen Myriad's balance sheet and sharpen its strategic focus on the cancer care continuum. The deal is expected to close by early 2027, subject to regulatory approvals and customary closing conditions.…more
$5.86+0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9After-hours26.10.10 05:168-KKey event
MYRIAD GENETICS INC
Myriad Genetics has entered into a separation agreement with its former Chief Commercial Officer, Brian Donnelly. Under the terms, the company will pay a lump sum severance of $1,322,294 and accelerate the vesting of certain outstanding equity awards.…more
$5.86+0.38%vs prev closeView filingShare - 9.22After-hours26.09.23 05:124Ownership
MYRIAD GENETICS INC
Benjamin Richard Wheeler, an insider at Myriad Genetics, Inc., filed a Form 4 statement of changes in beneficial ownership of securities on September 21, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$5.86+0.38%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 22:05#●●●#●●●
Myriad Genetics Announces Positive Clinical Data for Precise MRD Platform…more
Myriad Genetics released new data from the MONSTAR-SCREEN-3 study demonstrating the effectiveness of its Precise MRD platform in detecting recurrence risk for colorectal and pancreatic cancers. The findings highlight the potential of whole-genome sequencing to improve post-surgical monitoring and patient management.…more
$5.86+0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoRegular26.10.21 01:37
●●●●●●●● ●●●●● ●●●●●●
Myriad Genetics has agreed to sell its struggling prenatal health testing business to Labcorp for $210 million in an all-cash deal. The divestiture allows Myriad to offload a declining segment while Labcorp aims to integrate these assets to drive future diagnostic revenue.…more
$5.86+0.38%vs prev closeShareBenzinga - 4d agoPre-market26.10.20 21:30
●●●●●●●● ●●●●● ●●●●●●
Myriad Genetics has entered a definitive agreement to sell its prenatal health testing business to Labcorp for $210 million in cash. The divestiture allows Myriad to sharpen its focus on its core cancer care strategy while strengthening its balance sheet.…more
$5.86+0.38%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report